{"organizations": [], "uuid": "37f4a3a5844995054929a676e08ac38ea62e0bbd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/kala-pharms-study/kala-pharma-posts-mixed-results-from-dry-eye-disease-drug-studies-idUSL4N1OS4H0", "country": "US", "domain_rank": 408, "title": "Kala Pharma posts mixed results from dry eye disease drug studies", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T14:22:00.000+02:00", "replies_count": 0, "uuid": "37f4a3a5844995054929a676e08ac38ea62e0bbd"}, "author": "", "url": "https://www.reuters.com/article/kala-pharms-study/kala-pharma-posts-mixed-results-from-dry-eye-disease-drug-studies-idUSL4N1OS4H0", "ord_in_thread": 0, "title": "Kala Pharma posts mixed results from dry eye disease drug studies", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}, {"name": "martina d'couto", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "kala pharma", "sentiment": "negative"}, {"name": "reuters staf", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "kala pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 23 PM / in 4 minutes Kala Pharma posts mixed results from dry eye disease drug studies Reuters Staff 1 Min Read \nDec 28 (Reuters) - Kala Pharmaceuticals Inc on Friday reported mixed results from two late-stage trials testing its drug to provide temporary relief from the signs and symptoms of dry eye disease. \nThe drug, KPI-121, met the main goals of reducing redness and discomfort in the eye in one trial, but failed to show statistical significance on a scale that tested patientsâ€™ eyes using a corneal staining technique. \nThe second trial met the main goal of reducing a sign of dry eye, but failed another main goal of reducing discomfort in the eye, a symptom of the disorder. Reporting by Manas Mishra and Tamara Mathias in Bengaluru; Editing by Martina D'Couto", "external_links": [], "published": "2018-01-05T14:22:00.000+02:00", "crawled": "2018-01-05T14:31:51.017+02:00", "highlightTitle": ""}